

## Darolutamide (Nubeqa®) In the Treatment of Non-Metastatic Castration Resistant Prostate Cancer

**Description:** The purpose of this PQI is to summarize the process for initiating and monitoring darolutamide therapy in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

### Background:

Darolutamide is an androgen receptor inhibitor indicated for the treatment of adult patients with<sup>1</sup>:

- nmCRPC in combination with ADT
- mCSPC in combination with docetaxel and androgen deprivation therapy (ADT)
- mCSPC in combination with ADT

Most common adverse reactions (>10% with a ≥2% increase over placebo) including laboratory test abnormalities<sup>1</sup>: increased AST, decreased neutrophil count, increased bilirubin, fatigue, and increased ALT

### PQI Process:

- Verify diagnosis of nmCRPC
- Ensure appropriate dose: darolutamide 600 mg (two 300 mg tablets) twice daily<sup>1</sup>
  - For patients with severe renal impairment (eGFR 15-29 mL/min) the recommended dose is 300 mg BID
  - For patients with moderate hepatic impairment (Child-Pugh class B) recommended dose is 300 mg BID
- Ensure patient is on androgen deprivation therapy; GnRH agonist or antagonist
- Obtain labs: complete blood count with differential and comprehensive metabolic panel, PSA, and testosterone at baseline, monthly, and as clinically indicated
- Check for clinically relevant drug interactions
  - Darolutamide concentrations may decrease with PGP and moderate/strong CYP3A4 inducers; avoid concomitant use
  - Darolutamide concentrations may increase with PGP and strong CYP3A4 inhibitors; monitor for increase adverse effects
- Darolutamide may increase concentrations of breast cancer resistance protein substrates
- Dose modifications for toxicities—for Grade ≥ 3 toxicity or other intolerable adverse events, withhold or reduce to 300 mg twice daily until symptom resolution
  - May resume 600 mg twice daily upon resolution
  - Doses < 300 mg twice daily not recommended

### Patient-Centered Activities:

- Provide patient with darolutamide [Patient Education Sheet](#)
- Ensure patient receiving concomitant gonadotropin releasing hormone antagonist
- Take twice daily
- Swallow tablets whole and take with food
- Missed dose: Take as soon as a dose is remembered prior to the next scheduled dose; do not take two doses together to make up for a missed dose

**IMPORTANT NOTICE:** NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual's sole responsibility to seek guidance from a qualified healthcare professional. *Updated 7.25.25 PQI-135*

- Review potential side effects including fatigue, decreased neutrophil count, pain in extremities, and rash
- Males with female partners of reproductive potential should use highly effective contraception during treatment and for one week after last dose due to risk of embryo-fetal toxicity
- Patient Assistance: [NCODA Financial Assistance Tool](#)

**References:**

1. [Nubega® \(darolutamide\) \[prescribing information\]](#).
2. Bastos DA, et al. Darolutamide for castration-resistant prostate cancer. *Onco Targets Ther.* 2019; 12: 8769 – 8777.
2. National Comprehensive Cancer Network. Prostate cancer.
3. Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. *New Eng J Med.* 2019; 380: 1235 – 1246.